Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Lyra Therapeutics Inc (LYRA)

Lyra Therapeutics Inc (LYRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 72,178
  • Shares Outstanding, K 13,005
  • Annual Sales, $ 0 K
  • Annual Income, $ -22,130 K
  • 60-Month Beta 0.12
  • Price/Sales 5,143.51
  • Price/Cash Flow N/A
  • Price/Book 1.56
Trade LYRA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -0.82
  • Number of Estimates 1
  • High Estimate -0.82
  • Low Estimate -0.82
  • Prior Year -0.46
  • Growth Rate Est. (year over year) -78.26%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.26 +5.41%
on 11/22/21
7.90 -29.75%
on 11/02/21
-2.11 (-27.55%)
since 10/26/21
3-Month
5.26 +5.41%
on 11/22/21
9.98 -44.39%
on 09/24/21
-1.59 (-22.27%)
since 08/26/21
52-Week
5.26 +5.41%
on 11/22/21
16.50 -66.36%
on 03/01/21
-7.41 (-57.18%)
since 11/25/20

Most Recent Stories

More News
Lyra Therapeutics to Highlight LYR-210 and LYR-220 Clinical Programs at Virtual Event with Leading Clinical CRS Experts

/PRNewswire/ -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise,...

LYRA : 5.55 (-1.94%)
Lyra Therapeutics Announces Publication of Positive LANTERN Results in the International Forum of Allergy & Rhinology

LYR-210 is the First Drug-Eluting Product Candidate to Demonstrate Statistically Significant Symptom Improvement for Six Months with a Single Administration in Surgically Naïve Chronic Rhinosinusitis...

LYRA : 5.55 (-1.94%)
Lyra Therapeutics Announces Four Abstracts Selected for Presentations at Upcoming ERS and ARS Meetings, Including New LANTERN 6-Month Follow-Up and Pharmacokinetic Data

LYR-210 Pharmacokinetic Study Chosen as a Top Clinical Abstract at ARS

LYRA : 5.55 (-1.94%)
Lyra Therapeutics Appoints Jason Cavalier as Chief Financial Officer

Seasoned investment banking executive brings extensive finance, partnering and M&A experience to the role

LYRA : 5.55 (-1.94%)
Lyra Therapeutics Announces Publication of Preclinical Pharmacokinetics and Drug Release characterization for XTreo™ Technology Platform in the American Journal of Rhinology & Allergy

Results demonstrate XTreo ™ technology platform provides targeted and sustained dosing of anti-inflammatory medication

LYRA : 5.55 (-1.94%)
Lyra Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

WATERTOWN, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained,...

LYRA : 5.55 (-1.94%)
Lyra Therapeutics to Host Virtual Chronic Rhinosinusitis KOL Event on August 31

WATERTOWN, Mass., Aug. 17, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained,...

LYRA : 5.55 (-1.94%)
Lyra Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Recent Accomplishments

- Successful EOP2 FDA meeting for LYR-210 in CRS; Phase 3 program on track to begin around year-end 2021 -

LYRA : 5.55 (-1.94%)
Lyra Therapeutics to Report Second Quarter 2021 Financial Results on August 9

WATERTOWN, Mass., July 26, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained,...

LYRA : 5.55 (-1.94%)
Lyra Therapeutics to Present at Upcoming Virtual Healthcare Conference

WATERTOWN, Mass., July 12, 2021 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA), a clinical-stage therapeutics company leveraging its proprietary XTreo™ platform to enable precise, sustained,...

LYRA : 5.55 (-1.94%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Lyra Therapeutics Inc. is a clinical-stage therapeutics company. It is focused on the development and commercialization of novel integrated drug and delivery solutions for patients with ear, nose and throat diseases. The company's proprietary technology platform, XTreo(TM), is designed to precisely and...

See More

Key Turning Points

3rd Resistance Point 6.08
2nd Resistance Point 5.94
1st Resistance Point 5.74
Last Price 5.55
1st Support Level 5.41
2nd Support Level 5.27
3rd Support Level 5.08

See More

52-Week High 16.50
Fibonacci 61.8% 12.21
Fibonacci 50% 10.88
Fibonacci 38.2% 9.56
Last Price 5.55
52-Week Low 5.26

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar